Kolexia
Lecendreux Michel
Psychiatrie
Hôpital Robert-Debré
Paris, France
194 Activités
422 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Narcolepsie Cataplexie Troubles du sommeil par somnolence excessive Envie de dormir Hypersomnie idiopathique Troubles de la veille et du sommeil Syndrome de Kleine-Levin Fatigue Prédisposition génétique à une maladie

Industries

Biocodex
9 collaboration(s)
Dernière en 2023
UCB
3 collaboration(s)
Dernière en 2021
Bioprojet Pharma
3 collaboration(s)
Dernière en 2023
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Efficacy and safety of pitolisant in children above 6 years with narcolepsy with and without cataplexy
Abstracts from the 17th World Sleep Congress   01 février 2024
Microglial activation in narcolepsy type 1
Abstracts from the 17th World Sleep Congress   01 février 2024
Relationship between sleep alteration and cognitive deficit in children with ADHD associated with OSAS: the importance to take into account dual diagnosis in children sleep medicine
Abstracts from the 17th World Sleep Congress   01 février 2024
Pharmacological management of narcolepsy in children and adolescents.
Journal of sleep research   04 décembre 2023
Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine   09 novembre 2023
Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy.
Nature communications   15 mai 2023
Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
The Lancet. Neurology   22 mars 2023
Description de la transition dans la narcolepsie de type 1
Le Congrès du Sommeil ®. Lille, 23-25 novembre 2022   01 mars 2023
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period: Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period
Essai Clinique (Bioprojet)   21 février 2023
Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
Sleep medicine   24 janvier 2023